Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...

New ASH guidelines outline optimal management for a subgroup of patients with leukemia that historically has been challenging to treat.Two papers published simultaneously in Blood Advances address ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...

IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.

Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...

Adding the immune checkpoint inhibitors (ICIs) ipilimumab and nivolumab to percutaneous hepatic perfusion may improve survival outcomes in patients with ...